Relay Therapeutics Inc. (RLAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RLAY POWR Grades
- Value is the dimension where RLAY ranks best; there it ranks ahead of 59.92% of US stocks.
- The strongest trend for RLAY is in Value, which has been heading up over the past 31 weeks.
- RLAY ranks lowest in Momentum; there it ranks in the 9th percentile.
RLAY Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for RLAY is 0.11 -- better than only 13.45% of US stocks.
- Relay Therapeutics Inc's stock had its IPO on July 16, 2020, making it an older stock than only 0.32% of US equities in our set.
- RLAY's price/sales ratio is 35.52; that's higher than the P/S ratio of 93.15% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Relay Therapeutics Inc are DRIO, HTBX, IONS, DCTH, and NERV.
- RLAY's SEC filings can be seen here. And to visit Relay Therapeutics Inc's official web site, go to relaytx.com.
RLAY Stock Price Chart Interactive Chart >
RLAY Price/Volume Stats
|Current price||$34.22||52-week high||$64.37|
|Prev. close||$34.25||52-week low||$26.44|
|Day high||$34.27||Avg. volume||687,389|
|50-day MA||$32.38||Dividend yield||N/A|
|200-day MA||$40.67||Market Cap||3.16B|
Relay Therapeutics Inc. (RLAY) Company Bio
Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
RLAY Latest News Stream
|Loading, please wait...|
RLAY Latest Social Stream
View Full RLAY Social Stream
Latest RLAY News From Around the Web
Below are the latest news stories about Relay Therapeutics Inc that investors may wish to consider to help them evaluate RLAY as an investment opportunity.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in fireside chats at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 pm ET and at the JMP Securities Life Science Conference on Thursday, June 17, 2021 at 10:30 am ET. The fireside chats will be webcast live and may be accessed from the Investor page of Relay Tx’s website under Events and Presentations. Within 24 hours following eac
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today reported first quarter 2021 financial results. “Since the start of 2021, we have been laser-focused on our mission for the year – execution. We continue to make progress on our clinical programs – RLY-1971, our SHP2 inhibitor partnered with Genentech, and RLY-4008, our FGFR2 inhibitor. Our PI3Kα mutant selective program is anticipated to enter IND enabling studies this year and we continue to advance our pipeline of precision oncology and genetic diseases programs,” said Sanjiv Patel, M.D., president and chief executive officer. “We also ...
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: A...
Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discoveryCAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patrick Riley, Ph.D., as senior vice president of artificial intelligence. Dr. Riley is an industry expert in artificial intelligence and machine learning, bringing 15 years of experience from Google and extensive knowledge in applying these technologies to drug discovery. Dr. Riley will lead a computational team and report to group head, Pat Walters. “We are excited to welcome Patrick to our computational organizati...
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. Within 24 hours following the fireside chat, an archived replay of the webcast will be available until August 13, 2021. About Relay TherapeuticsRelay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate disci...
RLAY Price Returns